Why Galena Biopharma, Inc. Shares Tumbled

Galena shares sour after reporting its Q4 results and disclosing an investigation by the Securities and Exchange Commission. Find out what this means for you.

Mar 18, 2014 at 1:33PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company focused on developing immunotherapeutic options to treat cancer, fell as much as 21% after reporting its quarterly results after the closing bell last night and disclosing an investigation by the Securities and Exchange Commission.

So what: For the quarter, Galena reported net revenue of $1.3 million, driven by sales of newly acquired FDA-approved drug Abstral for breakthrough cancer pain, and an operating loss of $12.4 million due to higher costs from ongoing clinical studies. In the year-ago quarter, Galena produced no revenue and delivered a smaller operating loss of just $5.6 million. Net loss, however, swelled due to $38.9 million in non-cash charges to $48.5 million, causing Galena to widely miss Wall Street's EPS estimates. On the positive side, though, Galena boosted its 2014 forecast for Abstral sales to a new range of $11 million-$15 million from its previous projections of $8 million-$12 million.

What really has investors up in arms is an admission on page 37 of its annual 10-K filing that "[i]n February 2014we learned that the SEC is investigating certain matters relating to our company and an outside investor-relations firm that we retained in 2013. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation." Concerns have been raised in recent weeks that Galena may have hired a stock promoter to boost the value of its shares (see here and here, for example). Apparently, this has created enough real buzz that the SEC is looking more closely into whether that was the case.

Now what: There are few biotech companies that are as polarizing as Galena Biopharma -- you generally either love it or hate it. This SEC investigation is clearly a blow to a company whose earnings report otherwise signaled -- with the exception of one-time non-cash charges -- that it may be headed in the right direction. Keep in mind, of course, that SEC investigations sometimes turn up nothing or can lead to nothing more than a slap on the wrist. On other occasions, they may lead to hefty fines, which Galena may have difficulty absorbing. There are a lot of possible outcomes here, and given that uncertainty surrounding this investigation, you're probably best off sticking to the sidelines until we have better clarity.

Galena Biopharma may offer investors a ton of potential, but even it could struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers